Please assess the completion status of the following clinical trial:

Trial Title: Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PWS confirmed by chromosome analysis~* Ages 5 years to 21 years~* BMI for age ≥ (greater-than or equal to)85th percentile~* Written informed consent and assent obtained and willingness to comply with the study schedule and procedures~* Free T4, Thyroid stimulating hormone (TSH) values in the normal range (either endogenous or with thyroxine replacement)~Exclusion Criteria:~* Patients with any other clinically significant disease that would have an impact on body composition, including diabetes mellitus, chronic inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders~* Concomitant use of an investigational drug or Octreotide in the past year~* Use of steroids for longer than 7 days within the past 30 days

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide (Type: EXPERIMENTAL): Octreotide to be administered by subcutaneous injection three times daily while on study
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to be administered by subcutaneous injection three times daily while on study

Based on this trial design, predict the completion outcome and termination type (if applicable).